Skip to content
Medical Health Aged Care, Research Development

HCF Research Foundation supports key colonoscopy study as screening age lowers to 45

HCF 3 mins read
Monash University Professor (Research) Denise O'Connor

THURSDAY, 20 JUNE 2024: As Australia marks Bowel Cancer Awareness Month this June, the HCF Research Foundation proudly highlights its support of a pivotal research project aimed at improving surveillance colonoscopy, a key tool in diagnosing and preventing bowel cancer.

Led by Monash University Professor (Research) Denise O'Connor, the "Value in Care – Optimising Surveillance Colonoscopy (VIC-COL)" study has been making significant strides since receiving HCF Research Foundation funding in 2022.

The research is especially timely with the government's recent announcement to extend the National Bowel Cancer Screening Program (NBCSP) to Australians aged 45-49 starting from 1 July 2024.

Bowel cancer is Australia’s second deadliest cancer, but highly treatable if caught early.

The VIC-COL study aims to ensure that surveillance colonoscopy resources are used most effectively, so that patients receive the right care at the right time, in line with best practice guidelines.

“Clinical practice guidelines produced by Cancer Council Australia and endorsed by the National Health and Medical Research Council provide guidance for healthcare professionals and their patients on the need for and timing of future surveillance colonoscopy,” said Professor O'Connor.

“By improving adherence to these guidelines, we can ensure high-quality care and better health outcomes for patients,” Professor O’Connor said.

With the upcoming inclusion of an additional 1.6 million Australians aged 45-49 in the NBCSP, it is more critical than ever to ensure that colonoscopy resources are efficiently allocated to those who most need them.

A surveillance colonoscopy is a follow-up procedure performed at appropriate intervals after an initial colonoscopy has detected pre-cancerous lesions, polyps, or cancer.

Unlike an initial colonoscopy, which is a diagnostic procedure used to investigate symptoms or as part of routine screening to detect abnormalities in the colon, a surveillance colonoscopy is conducted to monitor patients who have a higher risk of developing bowel cancer.

The study has shown remarkable progress within its first 18 months, working with six hospitals to refine initiatives like training nurse champions, conducting regular chart audits, and providing feedback to healthcare professionals to support guideline-concordant surveillance colonoscopy intervals.

Dr Chris Pettigrew, Head of the HCF Research Foundation said, "The HCF Research Foundation's continued support of the VIC-COL project exemplifies our commitment to translating research findings into real-world practice, with the aim of delivering better patient outcomes and more cost-effective and efficient health services.

"We're proud to champion projects like VIC-COL that have the potential to make a significant impact on delivering quality healthcare," Dr Pettigrew said.

For more information on the HCF Research Foundation and its initiatives, visit https://www.hcf.com.au/about-us/hcf-foundation.

ENDS


Key Facts:

·        Bowel cancer, also known as colorectal cancer, is Australia’s fourth most commonly diagnosed and second deadliest cancer. (1)

·        An estimated 15,531 Australians are told they have bowel cancer each year (299 a week), including 1,716 people under the age of 50. (2)

·        Bowel cancer claims the lives of 5,350 Australians every year (103 a week), including 315 people under the age of 50. (2)

·        The National Bowel Cancer Screening Program (NBCSP) is projected to generate over 100,000 colonoscopies annually, increasing demand on already strained services. (1)

·        The NBCSP will be extended to include Australians aged 45-49 starting from 1 July 2024.

REFERENCES

1. Bowel Cancer Australia

2. Worthington J, He E, Lew J-B, St John J, Horn C, Grogan P, Canfell K, Feletto E. Colonoscopies in Australia – how much does the National Bowel Cancer Screening Program contribute to colonoscopy use? Public Health Res Pract. 2023;33(1):e32342216. First published 8 December 2022.


About us:

ABOUT THE HCF RESEARCH FOUNDATION

The HCF Research Foundation’s mission is to improve the health and wellbeing outcomes for HCF members and all Australians by providing funding and support to encourage health services research for the benefit of all. Now in its 24th year, the HCF Research Foundation (the Foundation) is uniquely focused on supporting health services research, an area of research that does not receive significant fundings from other sources. The Foundation’s program aims to address issues of scale and significance in healthcare and to make a tangible impact in the delivery of health services for our members and all Australians. To learn more about the Foundation go to hcf.com.au/about-us/hcf-foundation

 

ABOUT HCF

HCF, Australia’s largest not-for-profit health fund protecting Australians since 1932, covers almost 2 million members with health and life insurance, travel, pet, home and car insurance. HCF has been awarded Outstanding Value Health Insurance by Canstar eight years in a row from 2016-2023. On average over the last ten years, HCF has paid out more cents in every dollar in premiums to members as benefits than the industry average. To learn more about HCF go to hcf.com.au/about-us

 


Contact details:

Joni Thomes 0475 576 738 or jthomes@hcf.com.au

Media

More from this category

  • Biotechnology, Medical Health Aged Care
  • 22/07/2024
  • 12:56
Illumina

Research into psychedelic medicines to treat anxiety wins ANS Illumina Neurogenomics Award 2024

Genomic technologies to discover biological markers, within the blood, that could predict patient response to psychedelic medicines such as psilocybin. MELBOURNE, AUSTRALIA, 22 July 2024 - Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the winner of the annual Australasian Neuroscience Society (ANS) Illumina Neurogenomics Research Award as Dr Andrew Gibbons from the Department of Psychiatry, School of Clinical Sciences at Monash Health. “Psilocybin, a chemical produced by hallucinogenic mushrooms, is a psychedelic medicine that has shown to meaningfully reduce symptoms of generalized anxiety during psychotherapy for patients. However, not all patients respond.…

  • Contains:
  • Industrial Relations, Medical Health Aged Care
  • 22/07/2024
  • 11:12
Australian Nursing and Midwifery Federation (Victorian Branch)

Bolton Clarke nurses and carers to hold stop-work rally – Mon 22 July, 1pm-2pm

WHATANMF Bolton Clarke members two-hour stop work and community rally for fair pay and conditionsACTU Secretary Sally McManus and VTHC Secretary Luke Hilakari will address the rally WHENMonday, 22 July 2024, 1pm-3pm. (Speakers will start 1.05pm sharp) WHEREoutside Bolton Clarke’s Victorian headquarters, 347 Burwood Highway, Forest Hill Bolton Clarke nurses, personal care workers and midwives will stop work for two hours on Monday 22 July to rally for better pay and conditions. For the past 18 months, the Australian Nursing and Midwifery Federation (Victorian Branch) has been negotiating wages and conditions on behalf of about 1700 members working across Bolton…

  • Contains:
  • Medical Health Aged Care
  • 22/07/2024
  • 08:00
Monash University

New guideline to improve reporting in precision medicine globally

Ensuring the best reporting in precision medicine research and ultimately the best outcome for patients is the goal of a new international guideline, the first of its kind. The guideline is produced by an international consortium, chaired by Professor Paul Franks from Lund University in Sweden and co-chaired by Dr Siew Lim from Monash University’s Eastern Health Clinical School. Precision medicine, which is designed specifically for each individual patient and their disease, maximises their chances of a favourable result.Until now there has been no standardised guideline for reporting research on precision medicine, which tailors treatment to unique aspects of each…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.